Replies to post #2679 on Dendreon Corp fka DNDNQ

[corpstrat]

I've done just that - subscribed to BSR. Some very good stuff there on several companies in addition to DNDN, and it's a very reasonably priced service. BSR seems to me to be of high integrity and strong insight into the prospects of various development drugs, with refreshing humility about guessing short-term price moves.

The idea of spotting mispriced situations - like DNDN - in this imperfect market requires the kind of expertise that BSR appears to provide. (I say "appears" because. although I identified DNDN initially on my own, I'm not qualified to second guess judgments about clinical trial results and FDA chances.)